Compugen Sets March 2 Earnings Release with EPS +171% Forecast, Appoints Michele Holcomb
Compugen Ltd. will release Q4 and full-year 2025 results on March 2, 2026, with consensus EPS of $0.05 per share (+171.4% year-over-year) and expected revenues of $17.87 million (+1,115.7% year-over-year). The company appointed molecular biology expert Michele Holcomb, Ph.D., to its board on February 12.
1. Upcoming Q4 and Full-Year Results
Compugen Ltd. has scheduled the release of its fourth-quarter and full-year 2025 financial results for March 2, 2026. Investors will look for management’s commentary on growth drivers and guidance for 2026.
2. Consensus Financial Estimates
Analysts forecast earnings of $0.05 per share for Q4, reflecting a 171.4% increase from a year ago, and revenues of $17.87 million, up 1,115.7% year-over-year. Consensus EPS and revenue estimates have remained unchanged over the past 30 days.
3. Board Appointment of Michele Holcomb
On February 12, Compugen added Michele Holcomb, Ph.D., to its board of directors. Holcomb brings extensive experience in molecular biology and drug development, strengthening the company’s scientific oversight.